Contrasting OmniAb (OABI) & Its Competitors

OmniAb (NASDAQ:OABI) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare OmniAb to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.

Valuation and Earnings

This table compares OmniAb and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OmniAb	$59.08 million	-$22.33 million	-25.35
OmniAb Competitors	$1.70 billion	$77.14 million	3.14

OmniAb’s peers have higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

58.7% of OmniAb shares are owned by institutional investors. Comparatively, 54.2% of shares of all “Commercial physical research” companies are owned by institutional investors. 7.0% of OmniAb shares are owned by company insiders. Comparatively, 13.8% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for OmniAb and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0	0	9	0	3.00
OmniAb Competitors	49	786	1320	30	2.61

OmniAb presently has a consensus price target of $10.00, suggesting a potential upside of 71.53%. As a group, “Commercial physical research” companies have a potential upside of 12.19%. Given OmniAb’s stronger consensus rating and higher probable upside, equities research analysts plainly believe OmniAb is more favorable than its peers.

Volatility and Risk

OmniAb has a beta of -0.55, suggesting that its share price is 155% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 5.48, suggesting that their average share price is 448% more volatile than the S&P 500.

Profitability

This table compares OmniAb and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	-6.38%	-4.33%
OmniAb Competitors	-981.28%	-103.74%	-19.67%

Summary

OmniAb beats its peers on 7 of the 13 factors compared.

OmniAb Company Profile

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.